Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cannabis and the brain.

Leslie Iversen1

  • 1Department of Pharmacology, University of Oxford, Oxford, UK. les.iverson@pharm.ox.ac.uk

Brain : a Journal of Neurology
|May 24, 2003
PubMed
Summary
This summary is machine-generated.

Delta(9)-tetrahydrocannabinol, the active compound in cannabis, acts via CB(1) cannabinoid receptors. Research explores its effects on neurotransmitter release, cognitive function, and potential medical uses for conditions like multiple sclerosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Pharmacology of Phytocannabinoids.

Progress in the chemistry of organic natural products·2017
Same author

Designer psychostimulants: pharmacology and differences.

Neuropharmacology·2014
Same author

An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.

Bioorganic & medicinal chemistry letters·2013
Same author

Julius Axelrod: 20 May 1912 - 29 December 2004.

Biographical memoirs of fellows of the Royal Society. Royal Society (Great Britain)·2008
Same author

Neurotransmitter transporters and their impact on the development of psychopharmacology.

British journal of pharmacology·2006
Same author

Long-term effects of exposure to cannabis.

Current opinion in pharmacology·2005

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cannabinoid Research

Background:

  • Delta(9)-tetrahydrocannabinol (THC) is the primary psychoactive compound in cannabis.
  • CB(1) cannabinoid receptors mediate THC's central nervous system effects.
  • GABAergic interneurons in the hippocampus, amygdala, and cortex express high levels of CB(1) receptors.

Purpose of the Study:

  • To review the mechanisms of action of cannabinoids, focusing on CB(1) receptors.
  • To summarize the central effects of cannabinoids, including behavioral and cognitive impacts.
  • To discuss the potential therapeutic applications and risks associated with cannabis use.

Main Methods:

  • Review of existing scientific literature on cannabinoid pharmacology and neuroscience.
  • Analysis of studies involving CB(1) receptor antagonists and knockout mice models.

Related Experiment Videos

  • Examination of research on endocannabinoids, such as anandamide and 2-arachidonylglycerol.

    • Main Results:

    • CB(1) receptor activation inhibits neurotransmitter release.
    • Cannabinoids affect psychomotor behavior, memory, appetite, pain perception, and nausea.
    • Chronic cannabis use may lead to tolerance, dependence, and mild cognitive impairment, but evidence for irreversible neuropathology or a causal link to psychiatric illness is limited.

    Conclusions:

    • Cannabinoids, acting through CB(1) receptors, have diverse central effects.
    • Endocannabinoids play a role in synaptic modulation.
    • Further research into cannabinoid-based medicines may offer new therapeutic strategies for conditions like multiple sclerosis.